CompanyLTGONasdaqThousand Oaks, CA

Latigo Biotherapeutics

Latigo Biotherapeutics is a clinical-stage company developing oral Nav1.8 ion channel inhibitors for pain.

SEC EDGAR ClinicalTrials.gov latigobio.com

424B4Sep 18Latest SEC filing

Sep 3Latest story

September 2026

Latigo reports Q2 2026 results, NEJM publication for onzotrigine, and completed IPO

Sep 3Quarterly updateLatigo Biotherapeutics

August 2026

Latigo Biotherapeutics prices IPO at $18 per share on Nasdaq

Aug 7FinancingLatigo Biotherapeutics

July 2026

Latigo Biotherapeutics files for IPO on Nasdaq under ticker LTGO

Jul 17FinancingLatigo Biotherapeutics